(firstQuint)Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury.

 Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with acute lung injury,open label, controlled prospective study.

 Every patient will maintain their standard treatment of acute lung injury, with maximum tolerated dosage without side effects.

 The day of infusion will be considered day zero.

 From that moment, followup will be divided into 2,7,14 days.

 Clinical results will be analyzed after completion of 14 days of followup.

.

 Human Umbilical-Cord-Derived Mesenchymal Stem Cell Therapy in Acute Lung Injury@highlight

Phase I-II Clinical Trial - Safety and efficacy of umbilical-cord-derived mesenchymal stem cell (UC-MSC) in patients with Acute Lung Injury ,open label, controlled prospective study.

